Indiplon is a non-benzodiazepine sedative-hypnotic agent primarily developed for the treatment of insomnia. It belongs to the class of compounds known as pyrazolopyrimidines and acts as a selective modulator of the GABA-A receptor, enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) in the central nervous system. Indiplon is characterized by its rapid onset of action, making it suitable for both sleep onset and maintenance. Its pharmacokinetic profile includes a short half-life, which reduces the risk of next-day sedation, a common concern with longer-acting sleep medications. The substance is typically administered in oral form and has been studied for its efficacy and safety in various clinical trials. However, it is important to note that while Indiplon has shown promise, its development has faced challenges, and it may not be widely available in all markets. As with any medication, potential side effects and contraindications should be considered, and it is essential to consult healthcare professionals for appropriate use.

Indiplon

325715-02-4: Acetamide, N-methyl-N-[3-[3-(2-thienylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]-, N-Methyl-N-[3-[3-(2-thienylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]acetamide, N-Methyl-N-[3-[3-(thien-2-ylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]acetamide, N-methyl-N-{3-[3-(thiophen-2-ylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl}acetamide, Nbi 34060, Indiplon

Applications Sedative, hypnotic
References Wegner, F., et al.: J. Neurochem., 107, 1056 (2008), McDonald, L., ewt al.: Psychopharmacol., 197, 591 (2008), Wegner, F., et al.: Eur. J. Pharmacol., 580, 1 (2008),


CAS 325715-02-4: Indiplon

Indiplon

Ref: TR-I527200